Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
Titel:
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
Auteur:
Cahn, Pedro Madero, Juan Sierra Arribas, José Ramón Antinori, Andrea Ortiz, Roberto Clarke, Amanda E Hung, Chien-Ching Rockstroh, Jürgen K Girard, Pierre-Marie Sievers, Jörg Man, Choy Currie, Alexander Underwood, Mark Tenorio, Allan R Pappa, Keith Wynne, Brian Fettiplace, Anna Gartland, Martin Aboud, Michael Smith, Kimberly